SLN360
Silence Therapeutics
[]
$sln silence therapeutics presents new analysis from sln360 phase 1 single dose study in high lipoprotein(a) at the american heart association (aha) 2022 annual meeting 
Be the First to Know Which #PennyStocks Are Being Promoted - Not the Last! Real-Time #StockAlert Tracking and Monitoring: https://t.co/WLRj8z0R5p